Dr. Rami Burstein

It is now time to redirect the flow of #training in #headache research starting with onsite clinical #education in areas lacking a solid background. #OneHealthForHeadaches mdpi.com/1660-4601/20/6…

Our study in @JCephalalgia shows presence/absence of non-ictal #allodynia can be used to identify #galcanezumab responders with close to 80% accuracy and galcanezumab non-responders with close to 85% accuracy #migraine #headache #CGRP @ahsheadache 👉 bit.ly/3XvS36k

Predicting response to anti-CGRP mABs. This study found that older age, fewer prior treatment failures and no past history of immuno-rheumatologic disease may be associated with a better response to aforementioned therapy. rdcu.be/c7q7N #migraine #headache

Even a mild decrease in #migraine frequency by CGRP monoclonal antibody, #galcanezumab, is sufficient to partially reverse the excitability and responsivity of #neurons involved in generation of certain #triggers and potentially #premonitory symptoms 👉 bit.ly/3lfFqzw

A CGRP monoclonal antibody, #galcanezumab, reduced incidence of #headache after occurrence of common premonitory symptoms and triggers in those patients in which it reduced migraine frequency by>30,>50 and>70%, but not by<30% @NeuroPsychBMC #migraine 👇 …alofheadacheandpain.biomedcentral.com/articles/10.11…

"Non-ictal cephalic allodynia can be used to predict galcanezumab responders with nearly 80% accuracy and galcanezumab non-responders with nearly 85% accuracy". Find out more at: doi.org/10.1177/033310… #migraine #headache #ichd3matters

Proposed explanation for why and how non-ictal #allodynia interferes with ability of CGRP monoclonal antibody, #galcanezumab, to prevent initiation of next headache. This may have clinical implications. #migraine #CGRP @JCephalalgia In our latest study👉bit.ly/3IkP7W0

@SaitAshina Very informative.

Headache diary is an important tool that can assist the #diagnosis of medication overuse #headache, help to monitor frequency of headache and track the medication use #migraine #diagnostic

@LisaGfrerer and colleagues including @bidmcheadache @ramiburstein demonstrated that in responders, onabotA reduces proinflammatory gene expression and immune cell density mainly in calvarial periosteum and less so in neck muscles and fascia #migraine #Inflammation #painrelief

.@JCephalalgia @ihs_official @arne_may - Open Access for @JCephalalgia read the editorial - doi.org/10.1177/033310…

Our data shows that narrow band #green light reduces migrainous headache, #photophobia, #anxiety and improves sleep in majorly of patients with #migraine #AANAM 2022 @ramiburstein

Gfrerer et al. shed new light on how onabotulinumtoxinA helps prevent occipital headache and neck pain. bit.ly/3zhxDnf

@DiseasePrimers Difficult to treat with so little understanding of pathophysiogy. Very well written. Kudos .

Position number 6: we find our PrimeView on Tension-type #headache. #BestOf2021 go.nature.com/3feRWtw

Chronification of tension-type #headache involves sensitization of #spinal and supraspinal #neurons, and decreased antinociceptive activity from the brain go.nature.com/2Pn2VpU

@DiseasePrimers Great review

@SaitAshina @DiseasePrimers Great review. Congrats.

Our latest extensive review on tension-type headache #headache #tensiontypeheadache @DiseasePrimers 👇

@ihs_official Great paper. Important topic. Waiting fir a breakthrough in understanding and treatment

Learn more at: thelancet.com/journals/laneu… #menstrualmigraine #migraine

#FridayFacts Menstrual migraine affects about 18–25% of female migraineurs, and some studies found the menstrual migraine is more disabling and more challenging to treat. The possible underlying mechanisms include estrogen withdrawal and prostaglandin release.